Intellia Therapeutics Inc... (NTLA)

The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Pha...

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors...

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Sec...

Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test result...

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.